Heparin's effect on primary hemostasis detected by PFA-200

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F21%3A10432290" target="_blank" >RIV/00064203:_____/21:10432290 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/21:10432290

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=fL6on0RH29" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=fL6on0RH29</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Heparin's effect on primary hemostasis detected by PFA-200

Popis výsledku v původním jazyce

Heparin is widely used in clinical practice; its effect on secondary hemostasis is well known, but its effects on primary hemostasis are controversial. The Innovance (R) Platelet Function Analyzer-200 (TM) (PFA-200) performs a group of tests that evaluate the primary hemostasis of whole blood. It is frequently used in critically ill patients, but the effect of heparin on its results expressed as closure time is controversial. The purpose of this study was to describe whether different types and doses of heparin may influence closure time results on PFA-200 devices. For this study, 30 patients were recruited and divided into three groups based on the type and dose of heparin being administered. The first group included ten patients who were treated with a high dose of unfractionated heparin (concentration from 3 to 4 mg/kg) before commencement of cardiopulmonary bypass during cardiac surgery. The second group consisted of ten patients from both vascular and thoracic surgery who were administered a low dose of unfractionated heparin (concentration 1 mg/kg). The remaining ten patients from intensive care units received a prophylactic dose of low-molecular-weight heparin monitored by anti-Xa. We compared closure times on PFA-200 devices with collagen/ADP and collagen/epinephrine cartridges before and after anticoagulant administration. The results showed that only a high dose of unfractionated heparin prolonged the collagen/ADP closure time. The other groups failed to show any difference. We consider this finding to be important for clinicians using extracorporeal systems to differentiate primary hemostasis pathology caused by heparin or by extracorporeal devices themselves.

Název v anglickém jazyce

Heparin's effect on primary hemostasis detected by PFA-200

Popis výsledku anglicky

Heparin is widely used in clinical practice; its effect on secondary hemostasis is well known, but its effects on primary hemostasis are controversial. The Innovance (R) Platelet Function Analyzer-200 (TM) (PFA-200) performs a group of tests that evaluate the primary hemostasis of whole blood. It is frequently used in critically ill patients, but the effect of heparin on its results expressed as closure time is controversial. The purpose of this study was to describe whether different types and doses of heparin may influence closure time results on PFA-200 devices. For this study, 30 patients were recruited and divided into three groups based on the type and dose of heparin being administered. The first group included ten patients who were treated with a high dose of unfractionated heparin (concentration from 3 to 4 mg/kg) before commencement of cardiopulmonary bypass during cardiac surgery. The second group consisted of ten patients from both vascular and thoracic surgery who were administered a low dose of unfractionated heparin (concentration 1 mg/kg). The remaining ten patients from intensive care units received a prophylactic dose of low-molecular-weight heparin monitored by anti-Xa. We compared closure times on PFA-200 devices with collagen/ADP and collagen/epinephrine cartridges before and after anticoagulant administration. The results showed that only a high dose of unfractionated heparin prolonged the collagen/ADP closure time. The other groups failed to show any difference. We consider this finding to be important for clinicians using extracorporeal systems to differentiate primary hemostasis pathology caused by heparin or by extracorporeal devices themselves.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30223 - Anaesthesiology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Anesteziologie &amp; intenzivní medicína

ISSN

1214-2158

e-ISSN

—

Svazek periodika

32

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

5

Strana od-do

131-135

Kód UT WoS článku

000695465400002

EID výsledku v databázi Scopus

2-s2.0-85116072975